Zeke Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Zeke Capital Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$624K	Buy	5,113 +1,262	+33%	+$147K	0.04%	206
2022 Q3	$398K	Hold	3,851	–	–	0.03%	249
2022 Q2	$358K	Hold	3,851	–	–	0.02%	275
2022 Q1	$452K	Buy	3,851 +834	+28%	+$96.6K	0.02%	250
2021 Q4	$406K	Buy	3,017 +648	+27%	+$96.4K	0.02%	184
2021 Q3	$378K	Hold	2,369	–	–	0.02%	179
2021 Q2	$312K	Buy	2,369 +647	+38%	+$86.2K	0.02%	211
2021 Q1	$222K	Buy	1,722 +288	+20%	+$43.8K	0.02%	263
2020 Q4	$239K	Buy	+1,434	New	+$237K	0.02%	240

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Zeke Capital Advisors's ASND Position: Q4 2022 in Review

Zeke Capital Advisors increased its Ascendis Pharma A/S (ASND) stake by 33% in Q4 2022, buying an estimated $147K and bringing the position to 5,113 shares worth $624K. The position accounts for 0.04% of the portfolio, ranked #206.

Zeke Capital Advisors first reported a position in ASND in Q4 2020 and has held it in 9 quarters since. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

Zeke Capital Advisors held 5,113 shares of Ascendis Pharma A/S worth $624K as of Q4 2022.
Zeke Capital Advisors bought 1,262 Ascendis Pharma A/S shares in Q4 2022, an estimated $147K.
Ascendis Pharma A/S made up 0.04% of Zeke Capital Advisors's portfolio in Q4 2022, its #206 holding.
Zeke Capital Advisors first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 9 quarters since.
187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.